Clinical trial NCT03719183 - References

Acute Myeloid Leukemia — Comparison of Diagnostic Yield Among M-FISH, FISH Probe Panel and Conventional Cytogenetic Analysis in AML

Citation(s)

•   Ashok V, Ranganathan R, Chander S, Damodar S, Bhat S, S NK, A SK, Jadav SS, Rajashekaraiah M, T S S
  Comparison of Diagnostic Yield of a FISH Panel Against Conventional Cytogenetic Studies for Hematological Malignancies: A South Indian Referral Laboratory Analysis Of 201 Cases. Asian Pac J Cancer Prev. 2017 Dec 29;18(12):3457-3464.
•   Cantú ES, Dong H, Forsyth DR, Espinoza FP, Papenhausen PR
  Discrepant Cytogenetic and Interphase Fluorescence In Situ Hybridization (I-FISH) Results from Bone Marrow Specimens of Patients with Hematologic Neoplasms. Ann Clin Lab Sci. 2018 May;48(3):264-272.
•   He R, Wiktor AE, Hanson CA, Ketterling RP, Kurtin PJ, Van Dyke DL, Litzow MR, Howard MT, Reichard KK
  Conventional karyotyping and fluorescence in situ hybridization: an effective utilization strategy in diagnostic adult acute myeloid leukemia. Am J Clin Pathol. 2015 Jun;143(6):873-8. doi: 10.1309/AJCPP6LVMQG4LNCK. Erratum in: Am J Clin Pathol. 2015 Jul;144(1):175. Howard, Matthew H [corrected to Howard, Matthew T].
•   Kearney L
  Multiplex-FISH (M-FISH): technique, developments and applications. Cytogenet Genome Res. 2006;114(3-4):189-98. Review.
•   Kokate P, Dalvi R, Koppaka N, Mandava S
  Prognostic classification of MDS is improved by the inclusion of FISH panel testing with conventional cytogenetics. Cancer Genet. 2017 Oct;216-217:120-127. doi: 10.1016/j.cancergen.2017.05.004. Epub 2017 Aug 16.
•   Mohr B, Bornhäuser M, Thiede C, Schäkel U, Schaich M, Illmer T, Pascheberg U, Ehninger G
  Comparison of spectral karyotyping and conventional cytogenetics in 39 patients with acute myeloid leukemia and myelodysplastic syndrome. Leukemia. 2000 Jun;14(6):1031-8.
•   Peterson JF, Aggarwal N, Smith CA, Gollin SM, Surti U, Rajkovic A, Swerdlow SH, Yatsenko SA
  Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing? Oncotarget. 2015 Aug 7;6(22):18845-62.
•   Sreekantaiah C
  FISH panels for hematologic malignancies. Cytogenet Genome Res. 2007;118(2-4):284-96. Review.
•   Vance GH, Kim H, Hicks GA, Cherry AM, Higgins R, Hulshizer RL, Tallman MS, Fernandez HF, Dewald GW
  Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900). Leuk Res. 2007 May;31(5):605-9. Epub 2006 Sep 22.
•   Wheeler FC, Kim AS, Mosse CA, Shaver AC, Yenamandra A, Seegmiller AC
  Limited Utility of Fluorescence In Situ Hybridization for Recurrent Abnormalities in Acute Myeloid Leukemia at Diagnosis and Follow-up. Am J Clin Pathol. 2018 Mar 29;149(5):418-424. doi: 10.1093/ajcp/aqy002.
•   Wolff DJ, Bagg A, Cooley LD, Dewald GW, Hirsch BA, Jacky PB, Rao KW, Rao PN; Association for Molecular Pathology Clinical Practice Committee; American College of Medical Genetics Laboratory Quality Assurance Committee
  Guidance for fluorescence in situ hybridization testing in hematologic disorders. J Mol Diagn. 2007 Apr;9(2):134-43.
•   Zhang FF, Murata-Collins JL, Gaytan P, Forman SJ, Kopecky KJ, Willman CL, Appelbaum FR, Slovak ML
  Twenty-four-color spectral karyotyping reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia. Genes Chromosomes Cancer. 2000 Jul;28(3):318-28.

Comparison of Diagnostic Yield Among Multiplex Fluorescent in Situ Hybridization, Fluorescent in Situ Hybridization Probe Panel and Conventional Cytogenetic Studies in Acute Myeloid Leukemia

Details for clinical trial NCT03719183